Logo

AstraZeneca Reports Results of Imfinzi + tremelimumab in P-III (HIMALAYA) Trial for the Treatment of Hepatocellular Carcinoma

Share this

AstraZeneca Reports Results of Imfinzi + tremelimumab in P-III (HIMALAYA) Trial for the Treatment of Hepatocellular Carcinoma

Shots:

  • The P-III (HIMALAYA) trial evaluates Imfinzi (1500mg, q4w) + tremelimumab (300mg) vs sorafenib in 1324 patients with HCC prior not treated with systemic therapy & not eligible for LRT at 190 centers across 16 countries
  • The results showed an improvement in OS, 22% reduction in risk of death, m-OS (16.4mos. vs 13.8mos.), patients were alive @3yrs. (31% vs 20%), improvement in ORR (20.1% vs 5.1%), m-DoR (22.3mos. vs 18.4mos.), no bleeding risk, safety profiles were consistent with a known profile of product & no new safety signals
  • Treatment discontinuation due to AEs (8.2% & 4.1% vs 11%). Imfinzi is being studied as monothx. & combination with other anti-cancer treatments for solid tumors

Ref: AstraZeneca | Image: Mint

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions